Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Structure-Activity Relationship Analysis and hERG Liability Assessment of Second-Generation Antibiofilm Compounds Active Against Salmonella.

Created on 13 Jul 2026

Authors

Amy Sorge, Aliyah N Bennett, Sophia E Gregory, Allysa L Cole, Katherine J Woolard, Ansley M Nemeth, Andrew H Crow, Roberta J Melander, John S Gunn, Christian Melander

Published in

ChemMedChem. Volume 21. Issue 13. Pages e70363. Jul 14, 2026.

Abstract

Typhoid fever is a life-threatening illness caused by Salmonella enterica subspecies enterica serovar Typhi. The organ most implicated in chronic carriage and host transmission is the gallbladder due to bacterial biofilm formation on gallstones. Biofilms facilitate chronic infection because bacteria in biofilms are less susceptible to antibiotic treatment and immune factors in comparison to their planktonic brethren. Previously, we reported compounds that disrupt biofilms of Salmonella enterica serovar Typhimurium, a serovar closely related to S. Typhi, both in vitro and in vivo. This work extends the development of Salmonella antibiofilm agents through the further exploration of the parent scaffold. Lead antibiofilm compounds were tested for human ether-a-go-go-related gene (hERG) channel inhibition, from which we report new lead compounds with improved antibiofilm activity and reduced hERG channel inhibition.

PMID:
42437701
Bibliographic data and abstract were imported from PubMed on 13 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement